NCT01028209

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Institute for Neurodegenerative Disorders · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The underlying goal of this study is to assess \[18F\] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.

Conditions

• Alzheimer Disease
• Parkinson Disease
• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	[18F] PBR06	Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.

Timeline

• Start date: 2009-11-01
• Primary completion: 2010-09-22
• Completion: 2010-09-22
• First posted: 2009-12-09
• Last updated: 2019-04-03

Locations

1 site across 1 country: United States